These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 8177534)
21. Evidence for cholecystokininA receptors in bovine adrenal chromaffin cells. Aarnisalo AM; Vainio PJ; Männistö PT; Vasar E; Tuominen RK Neuroreport; 1996 Sep; 7(13):2167-70. PubMed ID: 8930982 [TBL] [Abstract][Full Text] [Related]
22. Cytosolic Ca2+ evaluation in rabbit parietal cells: a novel method to screen gastrin receptor antagonists. Letari O; Mennuni L; Revel L; Colombo S; Makovec F Eur J Pharmacol; 1996 Jun; 306(1-3):325-33. PubMed ID: 8813647 [TBL] [Abstract][Full Text] [Related]
23. CCKB receptors mediate CCK-8S-induced activation of dorsal hippocampus CA3 pyramidal neurons: an in vivo electrophysiological study in the rat. Gronier B; Debonnel G Synapse; 1995 Oct; 21(2):158-68. PubMed ID: 8584977 [TBL] [Abstract][Full Text] [Related]
24. Individual differences in the feeding response to CCKB antagonists: role of the nucleus accumbens. Sills TL; Vaccarino FJ Peptides; 1996; 17(4):593-9. PubMed ID: 8804067 [TBL] [Abstract][Full Text] [Related]
25. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. O'Neill MF; Dourish CT; Iversen SD Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197 [TBL] [Abstract][Full Text] [Related]
26. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212 [TBL] [Abstract][Full Text] [Related]
29. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283 [TBL] [Abstract][Full Text] [Related]
30. Characterization of YM022: its CCKB/gastrin receptor binding profile and antagonism to CCK-8-induced Ca2+ mobilization. Saita Y; Yazawa H; Honma Y; Nishida A; Miyata K; Honda K Eur J Pharmacol; 1994 Oct; 269(2):249-54. PubMed ID: 7851501 [TBL] [Abstract][Full Text] [Related]
31. His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity. Jagerschmidt A; Guillaume-Rousselet N; Vikland ML; Goudreau N; Maigret B; Roques BP Eur J Pharmacol; 1996 Jan; 296(1):97-106. PubMed ID: 8720482 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Bertrand P; Böhme GA; Durieux C; Guyon C; Capet M; Jeantaud B; Boudeau P; Ducos B; Pendley CE; Martin GE Eur J Pharmacol; 1994 Sep; 262(3):233-45. PubMed ID: 7813588 [TBL] [Abstract][Full Text] [Related]
33. [Cholecystokinin receptors involved in the central and peripheral nervous control mechanisms in gastric acid secretion]. Watanabe K; Yano S; Mitani H Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):153-62. PubMed ID: 7959408 [TBL] [Abstract][Full Text] [Related]
34. Cholecystokinin-induced ventral root depolarization of neonate rat hemicord in vitro. Long SK Gen Pharmacol; 1993 Jan; 24(1):171-5. PubMed ID: 8097738 [TBL] [Abstract][Full Text] [Related]
35. The effect of drugs acting on CCK receptors and rat free exploration in the exploration box. Matto V; Harro J; Allikmets L J Physiol Pharmacol; 1997 Jun; 48(2):239-51. PubMed ID: 9223028 [TBL] [Abstract][Full Text] [Related]
36. CCKB receptor activation results in increased [3H]thymidine incorporation in rat glioma C6 cells. Kaufmann R; Henklein P; Nowak G Neuropeptides; 1995 Nov; 29(5):241-4. PubMed ID: 8587658 [TBL] [Abstract][Full Text] [Related]
37. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists. Singh L; Field MJ; Hill DR; Horwell DC; McKnight AT; Roberts E; Tang KW; Woodruff GN Eur J Pharmacol; 1995 Nov; 286(2):185-91. PubMed ID: 8605955 [TBL] [Abstract][Full Text] [Related]
38. Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain. Boden PR; Woodruff GN; Pinnock RD Br J Pharmacol; 1991 Mar; 102(3):635-8. PubMed ID: 1364831 [TBL] [Abstract][Full Text] [Related]
39. CCK modulates inhibitory synaptic transmission in the solitary complex through CCKB sites. Branchereau P; Champagnat J; Roques BP; Denavit-Saubie M Neuroreport; 1992 Oct; 3(10):909-12. PubMed ID: 1330059 [TBL] [Abstract][Full Text] [Related]
40. Impairment of stress adaptive behaviours in rats by the CCKA receptor antagonist, devazepide. Hernando F; Fuentes JA; Ruiz-Gayo M Br J Pharmacol; 1996 May; 118(2):400-6. PubMed ID: 8735644 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]